| Literature DB >> 28869492 |
Michael Lichtenauer1, Bernhard Wernly2, Bernhard Ohnewein3, Marcus Franz4, Bjoern Kabisch5, Johanna Muessig6, Maryna Masyuk7, Alexander Lauten8,9, Paul Christian Schulze10, Uta C Hoppe11, Malte Kelm12, Christian Jung13.
Abstract
The lactate/albumin ratio has been reported to be associated with mortality in pediatric patients with sepsis. We aimed to evaluate the lactate/albumin ratio for its prognostic relevance in a larger collective of critically ill (adult) patients admitted to an intensive care unit (ICU). A total of 348 medical patients admitted to a German ICU for sepsis between 2004 and 2009 were included. Follow-up of patients was performed retrospectively between May 2013 and November 2013. The association of the lactate/albumin ratio (cut-off 0.15) and both in-hospital and post-discharge mortality was investigated. An optimal cut-off was calculated by means of Youden's index. The lactate/albumin ratio was elevated in non-survivors (p < 0.001). Patients with an increased lactate/albumin ratio were of similar age, but clinically in a poorer condition and had more pronounced laboratory signs of multi-organ failure. An increased lactate/albumin ratio was associated with adverse in-hospital mortality. An optimal cut-off of 0.15 was calculated and was associated with adverse long-term outcome even after correction for APACHE2 and SAPS2. We matched 99 patients with a lactate/albumin ratio >0.15 to case-controls with a lactate/albumin ratio <0.15 corrected for APACHE2 scores: The group with a lactate/albumin ratio >0.15 evidenced adverse in-hospital outcome in a paired analysis with a difference of 27% (95%CI 10-43%; p < 0.01). Regarding long-term mortality, again, patients in the group with a lactate/albumin ratio >0.15 showed adverse outcomes (p < 0.001). An increased lactate/albumin ratio was significantly associated with an adverse outcome in critically ill patients admitted to an ICU, even after correction for confounders. The lactate/albumin ratio might constitute an independent, readily available, and important parameter for risk stratification in the critically ill.Entities:
Keywords: ICU; albumin; critically ill patients; lactate; lactate/albumin ratio; risk score; risk stratification
Mesh:
Substances:
Year: 2017 PMID: 28869492 PMCID: PMC5618542 DOI: 10.3390/ijms18091893
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Laboratory and clinical baseline characteristics; survivors vs. non-survivors.
| Clinical Characteristics | Survivors | Non-Survivors | Overall Cohort | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SEM | Mean | SEM | Mean | SEM | |||||
| age | 63.67 | 14.71 | 67.67 | 12.02 | 64.97 | 14.00 | 0.01 | |||
| BMI (kg/m2) | 27.06 | 4.80 | 27.63 | 7.83 | 27.24 | 5.95 | 0.47 | |||
| SAPS2 (pts) | 46.43 | 16.70 | 58.57 | 19.37 | 50.58 | 18.55 | <0.001 | |||
| APACHE2 (pts) | 24.50 | 7.81 | 27.84 | 8.44 | 25.64 | 8.17 | 0.001 | |||
| lactate (mmol/L) | 2.19 | 0.50 | 20.58 | 3.77 | 0.70 | 22.90 | 2.50 | 0.50 | 22.90 | <0.001 |
| PCT (mmol/L) | 8.82 | 0.08 | 417.00 | 7.82 | 0.07 | 194.00 | 8.18 | 0.07 | 417.00 | 0.98 |
| glucose (mmol/L) | 9.9 | 3.9 | 30.0 | 10.4 | 3.8 | 39.4 | 10.1 | 3.8 | 30.0 | 0.11 |
| hemoglobin (mmol/L) | 6.60 | 2.50 | 10.30 | 6.60 | 4.80 | 8.90 | 6.60 | 2.5 | 10.30 | 0.35 |
| ASAT (μmol/L·s) | 0.85 | 0.20 | 222.27 | 1.07 | 0.20 | 154.50 | 0.89 | 0.20 | 222.27 | 0.02 |
| ALAT (μmol/L·s) | 0.58 | 0.08 | 41.81 | 0.73 | 0.10 | 71.70 | 0.63 | 0.08 | 71.70 | 0.03 |
| γ-GT (μmol) | 1.24 | 0.10 | 15.22 | 1.44 | 0.14 | 14.68 | 1.31 | 0.10 | 15.22 | 0.14 |
| bilirubin (μmol) | 17.0 | 1.8 | 405.0 | 19.0 | 3.0 | 551.0 | 18.0 | 1.8 | 551.0 | 0.28 |
| leucocytes (G/L) | 14.2 | 0.1 | 195.1 | 14.9 | 0.2 | 70.9 | 14.5 | 0.1 | 195.1 | 0.83 |
| BUN (mg/dL) | 12.8 | 1.9 | 59.6 | 19.5 | 0.5 | 80.2 | 14.4 | 0.5 | 80.2 | <0.001 |
| creatinine (mg/dL) | 15.0 | 30.0 | 1609.0 | 212.5 | 23.0 | 952.0 | 175.0 | 23.0 | 1609.0 | <0.001 |
| sodium (mmol/L) | 140 | 119 | 154 | 142 | 131 | 151 | 140 | 119 | 154 | 0.02 |
| potassium (mmol/L) | 4.1 | 2.5 | 9.3 | 4.5 | 3.1 | 10.8 | 4.2 | 2.5 | 10.8 | <0.001 |
| albumin (mg/L) | 20.00 | 10.00 | 57.00 | 18.00 | 10.00 | 27.00 | 19.00 | 10.00 | 57.00 | 0.01 |
| lactate/albumin ratio | 0.09 | 0.02 | 0.15 | 0.31 | 0.15 | 2.00 | 0.14 | 0.02 | 2.00 | <0.001 |
Laboratory and clinical baseline characteristics; lactate/albumin >0.15 vs. lactate/albumin <0.15.
| Clinical Characteristics | Lactate/Albumin <0.15 | Lactate/Albumin >0.15 | |||||
|---|---|---|---|---|---|---|---|
| Mean | SEM | Mean | SEM | ||||
| age | 63.70 | 14.75 | 66.23 | 12.69 | 0.09 | ||
| BMI (kg/m2) | 27.33 | 5.12 | 27.14 | 4.82 | 0.77 | ||
| SAPS2 (pts) | 47.81 | 18.03 | 59.01 | 20.82 | <0.001 | ||
| APACHE2 (pts) | 25.07 | 8.38 | 27.98 | 8.24 | <0.001 | ||
| lactate (mmol/L) | 1.7 | 0.5 | 5.9 | 5.9 | 1.8 | 26.0 | <0.001 |
| procalcitonin (mmol/L) | 6.5 | 0.1 | 161.9 | 10.1 | 0.2 | 188.6 | <0.001 |
| glucose (mmol/L) | 9.9 | 5.3 | 25.3 | 9.7 | 3.9 | 30.0 | 0.95 |
| hemoglobin (mmol/L) | 6.6 | 2.5 | 9.3 | 6.7 | 4.9 | 9.8 | 0.36 |
| ASAT (μmol/L·s) | 0.75 | 0.20 | 106.95 | 1.44 | 0.20 | 154.50 | <0.001 |
| ALAT (μmol/L·s) | 0.61 | 0.13 | 78.76 | 0.77 | 0.10 | 71.7 | <0.001 |
| γ-GT (μmol) | 1.29 | 0.1 | 15.22 | 1.3 | 0.14 | 20.33 | 0.92 |
| bilirubin (μmol) | 17.0 | 1.8 | 390.0 | 24.0 | 2.0 | 551.0 | <0.001 |
| leucocytes (G/L) | 12.9 | 0.1 | 50.5 | 15.4 | 0.1 | 96.8 | 0.06 |
| BUN (mg/dL) | 15.0 | 0.5 | 80.2 | 15.8 | 1.9 | 75.4 | 0.34 |
| creatinine (mg/dL) | 174 | 30 | 870 | 192 | 52 | 1332 | 0.34 |
| sodium (mmol/L) | 139 | 124 | 158 | 142 | 126 | 158 | 0.02 |
| potassium (mmol/L) | 4.2 | 2.9 | 7.1 | 4.5 | 2.8 | 12.4 | 0.01 |
| albumin (mg/L) | 21 | 10 | 60 | 17 | 10 | 30 | <0.001 |
An increased lactate/albumin ratio is associated with adverse in-hospital outcome.
| Parameter | HR | 95%CI | Non-Survivors Lactat/Albumin >0.15 | vs. | Non-Survivors Lactat/Albumin <0.15 | |
|---|---|---|---|---|---|---|
| lactate/albumin >0.15 | 4.27 | 2.42–7.52 | <0.001 | 54% | vs. | 18% |
Figure 1An increased lactate/albumin ratio is associated with adverse long-term outcome.
A lactate/albumin ratio >0.15 is associated with long-term mortality after correction for several confounders in a multivariate analysis.
| Multivariate Analysis | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| lactate/albumin >0.15 | 2.5 | 1.85–3.37 | <0.001 | 1.65 | 1.20–2.29 | 0.002 |
| APACHE2 | 1.05 | 1.03–1.07 | <0.001 | 1.05 | 1.03–1.07 | <0.001 |
| lactate/albumin >0.15 | 2.5 | 1.85-3.37 | <0.001 | 1.44 | 1.03–2.00 | 0.03 |
| SAPS2 | 1.03 | 1.02–1.04 | <0.001 | 1.03 | 1.02–1.04 | <0.001 |
| lactate/albumin >0.15 | 2.5 | 1.85–3.37 | <0.001 | 2.94 | 2.39–3.60 | <0.001 |
| glucose (mmol/L) | 1.01 | 0.99–1.03 | 0.41 | |||
| leucocytes (G/L) | 1.003 | 0.993–1.013 | 0.55 | |||
| heart rate (bpm) | 1.009 | 1.005–1.012 | <0.001 | |||
| ASAT (μmol/L·s) | 1.004 | 0.995–1.013 | 0.41 | |||
| ALAT (μmol/L·s) | 1.00 | 0.980–1.019 | 0.97 | |||
| BUN (mg/dL) | 1.034 | 1.025–1.044 | <0.001 | |||
| creatinine (mg/dL) | 0.999 | 0.998–0.999 | <0.001 | |||
Figure 2An increased lactate/albumin ratio is associated with long-term mortality in a matched-control analysis.